Improve Predictivity of your I/O Research with our Fully Immunocompetent Murine Models
With immunotherapy bringing massive treatment breakthroughs across a range of cancer types, novel preclinical immuno-oncology models are needed to tackle further development challenges and drive forward anticancer immunotherapy research. This includes models with functional immunity, to improve on research using immunodeficient mice.
CrownBio provides an extensive In Vivo Immunotherapy Translational Technology Platform, which includes a range of fully immunocompetent murine models. These are excellent tools to assess how cancer therapies perform within a fully functional immune system, for initial efficacy and PD testing of surrogate or cross-reactive agents and to advance compounds through preclinical study.
Syngeneic Models for Checkpoint Inhibitor Benchmarking and Large-Scale Drug Screening
Our suite of syngeneic tumor models provide a valuable system for assessing new single agent and combination immunotherapies within mice with fully competent immunity. We have over 40 syngeneic tumor models (including orthotopic and metastatic models) available and more in development.
CrownBio also provides MuScreen™ the first large-scale, in vivo screening platform for cancer immunotherapeutics. Using fixed sets of syngeneic tumor models, clients can rapidly focus immuno-oncology research efforts such as screening for efficacy, evaluating combination therapies, interrogating mechanism of action, and qualifying drug resistance in a cost-effective manner.
Murine Homograft Models - All The Pros of GEMMs with Added Consistency and Simplicity
Our syngeneic models are complemented by our murine homograft models, MuPrime™. Comprised of homografts of spontaneous murine tumors derived from GEMM/carcinogen-induced primary mouse tumor models, MuPrime combines the clinical relevance of GEMM with an operational simplicity, consistency, and robust growth for pharmacology research, including efficacy and PD assessment. Never passaged on plastic, the artificial selection pressure is minimized and the tumor architecture relevant to the original TME is preserved.
CrownBio’s collection of over 100 MuPrime models covers a wide diversity of cancer types, and enables preclinical research into, and discovery of, specific pathways and predictive biomarkers for targeted immunotherapy agents. MuScreen is now available with MuPrime tumor homografts for your higher throughput needs.
Validated Models to Guide Selection and Interpretation of Results
Our murine efficacy and PD models are fully validated with checkpoint inhibitor and treatment response data, immunoprofiling, and RNAseq providing confidence throughout our full In Vivo Immunotherapy Translational Technology Platform.
Contact us today for further information and for expert assistance in selecting the right murine immuno-oncology models for your preclinical research needs.